Oncolytics Biotech (NASDAQ:ONCY) is scheduled to announce its earnings results before the market opens on Monday, November 12th. Analysts expect the company to announce earnings of ($0.19) per share for the quarter.
Oncolytics Biotech (NASDAQ:ONCY) last announced its quarterly earnings results on Friday, August 3rd. The company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.04 by ($0.25). On average, analysts expect Oncolytics Biotech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
NASDAQ:ONCY traded down $0.04 on Tuesday, hitting $2.80. 1,000 shares of the stock were exchanged, compared to its average volume of 78,446. The firm has a market capitalization of $47.53 million, a PE ratio of -3.35 and a beta of 1.84. Oncolytics Biotech has a fifty-two week low of $2.60 and a fifty-two week high of $8.55.
Several equities research analysts have commented on ONCY shares. LADENBURG THALM/SH SH started coverage on Oncolytics Biotech in a research note on Monday, October 1st. They set a “buy” rating for the company. ValuEngine lowered Oncolytics Biotech from a “buy” rating to a “hold” rating in a research note on Thursday, July 26th.
ILLEGAL ACTIVITY WARNING: This news story was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/11/06/oncolytics-biotech-oncy-set-to-announce-quarterly-earnings-on-monday.html.
About Oncolytics Biotech
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.
Further Reading: Correction
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.